TCRX

TScan Therapeutics, Inc. (TCRX) | Rumor.io

TScan Therapeutics

TCRX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,766

Bullish sentiment (50-day avg)69%

Price to earnings ratio-0.34

Market capitalization22.2M

Earnings per share-0.9

Dividend yield (TTM)—

Revenue (annual)10.3M

Net income (annual)-129.8M

Social

What share of all stock conversation is about TCRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 2

TScan Therapeutics, Inc. has pivoted its focus to in vivo-engineered TCR-T solid tumor therapies and paused its Phase 3 ALLOHA-2 trial for TSC-101 to conserve capital.
The company has reduced its workforce by approximately 75% and expects its cash to last into the final quarter of 2027.
Despite the recent decline, TScan Therapeutics has a cash value per share of over $1 and a cash on hand of $122M, with a market capitalization of $25M.

Generated by AI

Sentiment

Of the messages about TCRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +66.67	73.08% +39.74	86.08% +1.08
Bearish	—	0% -66.67	26.92% -39.74	13.92% -1.08

Bullish· Nov 3

The author expects $TCRX to recover and potentially reach a price of $9 in the future, citing a strong pipeline and a high short interest.
The company's IND could be a catalyst for a significant price increase, potentially reaching $2 or more.
The author views the current price as a buying opportunity, citing oversold conditions and a strong support level, with a potential bounce expected in the near future.

Bearish· May 10

$TCRX's clinical pipelines are years away from making significant headway, with only Phase 1/2 programs.
The company is likely to burn through $30M in a year with subpar results.
$TCRX is expected to drop to $4 or lower, with some predicting a 10% decline.

Generated by AI

Topics

Of the messages about TCRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	17.5%	1.6%
Technical Analysis	—	—	72.5%	1.26%
Controversies	—	—	10%	0.15%
Analysts	—	—	0%	48.59%
Earnings	—	—	0%	0.06%
Macro	—	—	0%	48.34%

Announcements· Dec 26

TScan Therapeutics (TCRX) announced a $30 million registered direct offering at a 37% premium, extending its cash runway into Q1 2027.
The offering involves the sale of pre-funded warrants for up to 7,500,000 shares at $4.00 each, aiming to raise approximately $30 million.
The financing will fund operations into early 2027, with the company's stock experiencing a 24.05% premarket change and $2.05 million in volume.

Technical Analysis· May 9

$TCRX has formed a double bottom setup, indicating a potential bullish reversal, with a target above $5.
The stock has been manipulated, with manipulators setting traps for stop losses, and is currently respecting levels, which can indicate a high level of manipulation.
$TCRX has a clear accumulation pattern, with a potential target of $8-10, and is considered a multi-day gamer, with a bullish chart and room for further upside towards $9.5.

Generated by AI

Community

Of the messages about TCRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	19.54%	7.04%
Newcomers	—	0%	80.46%	92.96%

Regulars· May 10

* TScan Therapeutics reports first-quarter 2023 financial results, with GAAP EPS of -$0.93 and revenue of $6.80M.
* The company's stock price has shown strength, with a 26.0% increase and a short float of 0.7%.
* A.I.dvisor made a bullish call on TScan Therapeutics, resulting in a 49.78% gain over one week.

Newcomers· Sep 2

TScan Therapeutics has pivoted its strategy to focus on in vivo-engineered TCR-T solid tumor therapies, targeting an initial IND submission in Q3 2027.
The company has reduced its workforce by approximately 75% and suspended its Phase 3 ALLOHA-2 trial to conserve capital and extend its cash runway into Q4 2027.
Despite the recent decline, TScan still has a significant cash position, with a cash value per share over $1 and a total cash on hand of $122M as of June 26.

Generated by AI

News

TScan Therapeutics announces retention program for key executives

18d agoInvesting.com

H.C. Wainwright downgrades Tscan stock rating on restructuring

21d agoInvesting.com

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow (NASDAQ:TCRX) 2026-09-04

25d agoSeeking Alpha

Also Discussed

Investors talking about TCRX also mention

#	Name	Attention
1	Shengfeng Development Ltd.SFWL	0%0
2	Nkarta, Inc.NKTX	0%0
3	INZY - Inozyme Pharma, Inc.	——
4	GSI Technology Inc.GSIT	0%0
5	I-Mab Sponsored ADRIMAB	0%0
6	ImageneBio, Inc.IKNA	0%0
7	Caribou Biosciences, Inc.CRBU	0%new
8	LVTX - LAVA Therapeutics N.V.	——
9	ATXS - Astria Therapeutics, Inc.	——
10	IGMS - IGM Biosciences, Inc.	——

TScan Therapeutics, Inc.

Healthcare
Biotechnology

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer. The company’s current work centers on TCR-T programs designed to address hematologic malignancies and solid tumors, with lead candidates aimed at eliminating residual disease and reducing relapse risk after allogeneic hematopoietic cell transplantation. TScan Therapeutics also advances multiplexed TCR-T approaches for solid tumors and uses its platform to identify shared tumor antigens and evaluate off-target TCR interactions, supporting the selection of more precise therapeutic targets. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics operates in the immuno-oncology and cell therapy segments of biotechnology, where its pipeline reflects a focus on targeted, personalized cancer treatment development.

Website

Location

830 Winter Street

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about TCRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 2

TScan Therapeutics, Inc. has pivoted its focus to in vivo-engineered TCR-T solid tumor therapies and paused its Phase 3 ALLOHA-2 trial for TSC-101 to conserve capital.
The company has reduced its workforce by approximately 75% and expects its cash to last into the final quarter of 2027.
Despite the recent decline, TScan Therapeutics has a cash value per share of over $1 and a cash on hand of $122M, with a market capitalization of $25M.

Generated by AI

Sentiment

Of the messages about TCRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +66.67	73.08% +39.74	86.08% +1.08
Bearish	—	0% -66.67	26.92% -39.74	13.92% -1.08

Bullish· Nov 3

The author expects $TCRX to recover and potentially reach a price of $9 in the future, citing a strong pipeline and a high short interest.
The company's IND could be a catalyst for a significant price increase, potentially reaching $2 or more.
The author views the current price as a buying opportunity, citing oversold conditions and a strong support level, with a potential bounce expected in the near future.

Bearish· May 10

$TCRX's clinical pipelines are years away from making significant headway, with only Phase 1/2 programs.
The company is likely to burn through $30M in a year with subpar results.
$TCRX is expected to drop to $4 or lower, with some predicting a 10% decline.

Generated by AI

Topics

Of the messages about TCRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	17.5%	1.6%
Technical Analysis	—	—	72.5%	1.26%
Controversies	—	—	10%	0.15%
Analysts	—	—	0%	48.59%
Earnings	—	—	0%	0.06%
Macro	—	—	0%	48.34%

Announcements· Dec 26

TScan Therapeutics (TCRX) announced a $30 million registered direct offering at a 37% premium, extending its cash runway into Q1 2027.
The offering involves the sale of pre-funded warrants for up to 7,500,000 shares at $4.00 each, aiming to raise approximately $30 million.
The financing will fund operations into early 2027, with the company's stock experiencing a 24.05% premarket change and $2.05 million in volume.

Technical Analysis· May 9

$TCRX has formed a double bottom setup, indicating a potential bullish reversal, with a target above $5.
The stock has been manipulated, with manipulators setting traps for stop losses, and is currently respecting levels, which can indicate a high level of manipulation.
$TCRX has a clear accumulation pattern, with a potential target of $8-10, and is considered a multi-day gamer, with a bullish chart and room for further upside towards $9.5.

Generated by AI

Community

Of the messages about TCRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	19.54%	7.04%
Newcomers	—	0%	80.46%	92.96%

Regulars· May 10

* TScan Therapeutics reports first-quarter 2023 financial results, with GAAP EPS of -$0.93 and revenue of $6.80M.
* The company's stock price has shown strength, with a 26.0% increase and a short float of 0.7%.
* A.I.dvisor made a bullish call on TScan Therapeutics, resulting in a 49.78% gain over one week.

Newcomers· Sep 2

TScan Therapeutics has pivoted its strategy to focus on in vivo-engineered TCR-T solid tumor therapies, targeting an initial IND submission in Q3 2027.
The company has reduced its workforce by approximately 75% and suspended its Phase 3 ALLOHA-2 trial to conserve capital and extend its cash runway into Q4 2027.
Despite the recent decline, TScan still has a significant cash position, with a cash value per share over $1 and a total cash on hand of $122M as of June 26.

Generated by AI

TScan Therapeutics

Social

Sep 2

Bullish· Nov 3

Bearish· May 10

Announcements· Dec 26

Technical Analysis· May 9

Regulars· May 10

Newcomers· Sep 2

TScan Therapeutics announces retention program for key executives

H.C. Wainwright downgrades Tscan stock rating on restructuring

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow (NASDAQ:TCRX) 2026-09-04

Crude Oil Moves Higher; US Factory Orders Rise In July

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift

Also Discussed

TScan Therapeutics, Inc.

Company Information

Location

TScan Therapeutics announces retention program for key executives

H.C. Wainwright downgrades Tscan stock rating on restructuring

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow (NASDAQ:TCRX) 2026-09-04

Crude Oil Moves Higher; US Factory Orders Rise In July

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift

Also Discussed

Social

Sep 2

Bullish· Nov 3

Bearish· May 10

Announcements· Dec 26

Technical Analysis· May 9

Regulars· May 10

Newcomers· Sep 2